MedPage Today

FDA Approves Atezolizumab for Stage III Mismatch Repair-Deficient Colon Cancer

(MedPage Today) -- The FDA on Thursday approved intravenous atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in patients 2 years...